Treatment of α-galactosidase A deficiency

Details Treatment of α-galactosidase A deficiency Treatment of α-galactosidase A deficiency

2006-04-13

2010-11-16

Davis, Ruth A (Department: 1651)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving glucose or galactose

C435S018000, C424S094100, C424S094600

Reexamination Certificate

active

07833742

ABSTRACT:
The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included.

REFERENCES:
patent: 4407957 (1983-10-01), Lim
patent: 4740365 (1988-04-01), Yukimatsu et al.
patent: 4764376 (1988-08-01), Hirsch et al.
patent: 5179023 (1993-01-01), Calhoun et al.
patent: 5272066 (1993-12-01), Bergh et al.
patent: 5298400 (1994-03-01), Whitfeld et al.
patent: 5356804 (1994-10-01), Desnick et al.
patent: 5382518 (1995-01-01), Caput et al.
patent: 5401650 (1995-03-01), Desnick et al.
patent: 5654007 (1997-08-01), Johnson et al.
patent: 5658567 (1997-08-01), Calhoun et al.
patent: 5661132 (1997-08-01), Eriksson et al.
patent: 5697901 (1997-12-01), Eriksson
patent: 5733761 (1998-03-01), Treco et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5770405 (1998-06-01), Wong-Madden et al.
patent: 5780014 (1998-07-01), Eljamal et al.
patent: 5780045 (1998-07-01), McQuinn et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5798113 (1998-08-01), Dionne et al.
patent: 5804413 (1998-09-01), DeLuca
patent: 5814607 (1998-09-01), Patton
patent: 5834251 (1998-11-01), Maras et al.
patent: 5858751 (1999-01-01), Paulson et al.
patent: 6083725 (2000-07-01), Selden et al.
patent: 6410272 (2002-06-01), Meyhack et al.
patent: 6458574 (2002-10-01), Selden
patent: 6566099 (2003-05-01), Selden et al.
patent: 6607901 (2003-08-01), Schaffer et al.
patent: 2003/0049245 (2003-03-01), Mann et al.
patent: A21796/88 (1988-09-01), None
patent: B-21796/88 (1998-03-01), None
patent: 0 307 285 (1989-03-01), None
patent: 0 408 461 (1992-04-01), None
patent: A H01-165373 (1989-06-01), None
patent: H03-143393 (1991-06-01), None
patent: A H06-503479 (1994-04-01), None
patent: A H08-503615 (1996-04-01), None
patent: WO 90/11353 (1990-10-01), None
patent: WO 9011353 (1990-10-01), None
patent: WO 92/13067 (1992-01-01), None
patent: WO 92/06187 (1992-04-01), None
patent: WO 93/08292 (1993-04-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 94/12628 (1994-06-01), None
patent: WO 95/06478 (1995-03-01), None
patent: WO 98/11206 (1998-03-01), None
patent: WO 0053730 (2000-09-01), None
Bishop et al., “Purification and characterization of human alpha-galactosidase isozymes: comparison of tissue and plasma forms and evaluation of purification methods”, Birth Defects Original Article Ser., 16(1):17-32, 1980.
Parr, “Declaration of Conformity”, Biochrom, 1-33, 2001.
Pierce Tech Tip #6, “Extinction Coefficients”, Pierce Biotechnology, Inc., 1-3, 2006.
UniProt Accession No. P00924, “UniProtKB/Swiss-Prot entry P00924”, 1-8, Jul. 21, 1986.
Pastores et al., “Enzyme-replacement therapy for Anderson-Fabry disease,”Lancet, 358:601-603 (2001).
Nolte et al., “Hydrophobic Interaction Chromatography ofStaphylococcus aureusDelta-Toxin,”Infect. Immun., 31(3):1094-1098 (1981).
Ashwell et al., “Carbohydrate-Specific Receptors of the Liver” Ann. Rev. Biochem. 51:531-554, 1982.
Beutler, “Gaucher's Disease”, New Engl. J. Med. 325: 1354-1360 (1991).
Bishop, David et al., “Enzyme Therapy XX: Further for the Differential In Vivo Fate of Human Splenic and Plasma . . . , ”in Lysomomes and Lysosomal Storage Disease, Rave Press NY, 1981, pp. 381-394.
Bishop et al., “Human α-galactosidase A: Nucleotide sequence of a cDNA clone encloding the mature enzyme” Proc. Natl. Acad. Sci. USA 83:4859, 1986.
Bishop et al., “Affinity Purification of α-Galactosidase A from Human Spleen, Placenta, and Plasma with Elimination of Pyrogen Contamination”, The Journal of Biological Chemistry, vol. 256(3), pp. 1307-1316 (1981).
Brady et al., “Replacement Therapy for Inherited Enzyme Deficiency” N. Engl. J. Med. 289:9, 1973.
Calhoun et al., “Fabry disease: Isolation of a cDNA clone encoding human α-galactosidase A”, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 7364-7368 (1985).
Cuozzo et al., “Lysine-based Structure Responsible for Selective Mannose Phosphorylation of Cathepsin D and Cathepsin L Defines a Common Structural Motif for Lysosomal Enzyme Targeting”, J. Biol. Chem. 273: 1069-21076 (1998).
Delgado et al., Crit. Rev. Ther. Drug Carrier Syst. 9: 249.
Desnick et al., “Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic α-galactosidase A isozymes” Proc. Natl. Acad. Sci. USA 76:5326, 1979.
Desnick et al., “α-Galactosidase A Deficiency: Fabry Disease: Fabry Disease: The Metobolic and Molecular Basis of Inherited Disase”, Chapter 889, pp. 2741-2784.
Desnick et al., “Enzyme Therapy XVII: Metabolic and Immunologic Evaluation of α-Galactosidase A Replacement in Fabry Disease”, Birth Defects, vol. 16(1), pp. 393-413 (1980).
Diment et al., “Generation of Macrophage Variants With 5-Azacytidine: Selection for Mannose Receptor Expression”, J. Leukocyte Biol. 41: 485.
Edwards et al., Science 276: 1868-1872 (1997).
English Abstract of JP-A H01-165373 (MicroPatent Reference No. 002598242).
Eng et al., “A Phase 1/2 Clinical Trail of Enzyme . . . ”, Am J Hum Genet. Mar. 2001; 68(3): 71 1.
Eng et al., “Safety and Efficacy of Recombinant Human . . . ”, N Engl J Med. 2001 ,Jd5; 345(1): 9.
EPO search report for application No. 97942567.5, mailed Oct. 7, 2002.
First Office Action from Intellectual Property Office of the People's Republic of China in Application No. 97197909.X, mailed Sep. 13, 2002.
Francis et al., “PEGlyation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques”, Int. J. Hematol 68(1):1-18 (1998).
Garman et al., “The Molecular Defect Leading to Fabry Disease: Structure of Human α-Galactosidase”, J. Mol. Biol., vol. 337, pp. 319-335 (2004).
Grammatikos et al., Biotechnol. Prog. 14: 410-419 (1998).
Hantzopolous et al., Gene, 57: 159 (1987).
Hermentin et al., Glycobiology 6: 217-230 (1996).
Hokke et al., “Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain trace of N-glyoulmeuraminic acid”, Federation of European Biochemical Societies, vol. 27, No. 1, 2, pp. 9-14, (1990).
Hsiung et al., “High-Level Expression, Efficient Secretion and Folding of Human Growth Hormone inEscherichia coli” Biotechnology 4: 991-995 (1986).
Ihara et al., “cDNA Cloning, Expression, and Chromosomal Localization of HumanN-Acetylglucosaminyltransferase III (Gn-T-III)1”, J. Biochem. (Tokyo) 113: 692-698 (1993).
International Search Report for PCT/US00/06118 dated Feb. 23, 2005.
Ioannou et al., “Overexpression of Human a-galactosidase A results in its Intracellular Aggregation, Crystallization in Lysosomes and Selective Secretion”, J. Cell Biol. 119:1137, 1992.
Isidoro et al., “Suppression of the ‘uncovering’ of mannose-6-phosphate residues in lysosomal enzymes in the presence of NH4Cl”, Eur. J. Biochem. 191: :591-597 (1990).
Jenkins et al., “Getting the glycosylation right: Implications for the biotechnology industry”, Nature Biotechnology, vol. 14, pp. 975-981 (1996).
Kinstler et al., “Characterization and Stability ofN-terminally PEGylated rhG-CSF”, Pharm. Res. 13: 996-1002 (1996).
Körner et al., “Carbohydrate-deficient glycoprotein syndrome type V: Deficiency of dolichyl-P-Glc:Man9Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase”, Proc. Natl. Acad. Sci. USA 95:13200.
Kornfeld & Mellman, “Annual Review of Cell Biology: The Biogenesis of Lysosomes” 5: 483-525 (1989).
Kornreich et al., “Nucleotide sequence of the human α-galactosidase A gene”, Nucleic Acids Research; 17:3301, 1998.
Kukuruzinska & Lennon, “Protein N-Glycosylation: Molecular Genetics and Functiona

Affiliated with

Also associated with

Rating

Treatment of α-galactosidase A deficiency does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of α-galactosidase A deficiency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of α-galactosidase A deficiency will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227068